Brawn Biotech Limited (BOM:530207)
India
· Delayed Price · Currency is INR 20.27
-0.97 (-4.57%)
At close: Mar 6, 2026
Brawn Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 172.61 | 134.65 | 164.95 | 222.31 | 86.21 | 349.76 | Upgrade
|
| Other Revenue | 0.1 | 0.1 | - | 0.06 | 0 | - | Upgrade
|
| Revenue | 172.71 | 134.75 | 164.95 | 222.36 | 86.21 | 349.76 | Upgrade
|
| Revenue Growth (YoY) | 17.87% | -18.30% | -25.82% | 157.93% | -75.35% | -29.51% | Upgrade
|
| Cost of Revenue | 149.18 | 120.92 | 145.22 | 193.25 | 68.88 | 300.27 | Upgrade
|
| Gross Profit | 23.53 | 13.83 | 19.73 | 29.11 | 17.33 | 49.49 | Upgrade
|
| Selling, General & Admin | 7.34 | 11.44 | 17.04 | 15.94 | 21.91 | 26.06 | Upgrade
|
| Other Operating Expenses | 19.81 | 20.01 | 17.33 | 16.14 | 15.45 | 29.1 | Upgrade
|
| Operating Expenses | 28.38 | 32.59 | 35.36 | 33.17 | 37.9 | 55.5 | Upgrade
|
| Operating Income | -4.85 | -18.76 | -15.63 | -4.05 | -20.57 | -6.01 | Upgrade
|
| Interest Expense | -0.04 | -0.03 | -0.57 | -0.07 | -0.11 | -0.19 | Upgrade
|
| Interest & Investment Income | 0.82 | 0.82 | 0.88 | 0.03 | - | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.05 | - | 0.02 | 2.74 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.71 | -0 | -0.01 | -0.02 | -0.52 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | -1.38 | -17.99 | -15.38 | -4.12 | -21.18 | -3.6 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.06 | - | - | - | Upgrade
|
| Pretax Income | -1.37 | -17.98 | -15.44 | -4.12 | -21.18 | -3.6 | Upgrade
|
| Income Tax Expense | -0.58 | -0.58 | -2.97 | 4.57 | -4.73 | 1.91 | Upgrade
|
| Net Income | -0.79 | -17.4 | -12.47 | -8.68 | -16.44 | -5.51 | Upgrade
|
| Net Income to Common | -0.79 | -17.4 | -12.47 | -8.68 | -16.44 | -5.51 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| EPS (Basic) | -0.27 | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 | Upgrade
|
| EPS (Diluted) | -0.27 | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 | Upgrade
|
| Free Cash Flow | - | -1.94 | -0.38 | 2.22 | -1.09 | 0.33 | Upgrade
|
| Free Cash Flow Per Share | - | -0.65 | -0.13 | 0.74 | -0.36 | 0.11 | Upgrade
|
| Gross Margin | 13.62% | 10.27% | 11.96% | 13.09% | 20.10% | 14.15% | Upgrade
|
| Operating Margin | -2.81% | -13.92% | -9.48% | -1.82% | -23.86% | -1.72% | Upgrade
|
| Profit Margin | -0.46% | -12.91% | -7.56% | -3.90% | -19.07% | -1.57% | Upgrade
|
| Free Cash Flow Margin | - | -1.44% | -0.23% | 1.00% | -1.27% | 0.10% | Upgrade
|
| EBITDA | -3.23 | -17.61 | -15.12 | -2.96 | -20.04 | -5.67 | Upgrade
|
| EBITDA Margin | -1.87% | -13.07% | -9.17% | -1.33% | -23.24% | -1.62% | Upgrade
|
| D&A For EBITDA | 1.62 | 1.15 | 0.51 | 1.09 | 0.53 | 0.34 | Upgrade
|
| EBIT | -4.85 | -18.76 | -15.63 | -4.05 | -20.57 | -6.01 | Upgrade
|
| EBIT Margin | -2.81% | -13.92% | -9.48% | -1.82% | -23.86% | -1.72% | Upgrade
|
| Revenue as Reported | 176.25 | 135.58 | 165.83 | 222.4 | 86.24 | 352.85 | Upgrade
|
| Advertising Expenses | - | 0.17 | 0.27 | 0.29 | 0.71 | 0.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.